



Direct Healthcare Professional Communication

Vipranop 5 micrograms/ml (Noradrenaline) Solution for Injection and Infusion: potential risk of medication errors

July 2025

Dear Healthcare Professional

Laboratoire Aguettant in agreement with the Medicines and Healthcare products Regulatory Agency (MHRA), would like to inform you of the following:

Summary

A new Noradrenaline product, **Vipranop 5 micrograms/ml, solution for injection/infusion**, has been approved for the restoration and maintenance of blood pressure following hypotension induced by spinal or general anaesthesia in adults.



- *This product differs from existing Noradrenaline products in both strength and presentation.*
- *There is a potential risk of underdosing or overdosing should the incorrect strength of noradrenaline be administered, and risk of serious adverse drug reactions or lack of efficacy.*
- *Prescribers should always specify the dosage of noradrenaline on each prescription (quantities less than 1 mg should be written in micrograms and not abbreviated to mg).*
- *Healthcare professionals should check whether the product requires dilution before administration.*



The table below outlines the differences between the available noradrenaline products:

	New Product	Existing Product		
Name	Vipranop 5 µg/mL, solution for injection/infusion	Noradrenaline 0.08 mg/ml solution for infusion	Sinora 0.16 mg/ml solution for infusion	Noradrenaline Concentrate for solution for infusion
Strength	5 µg/mL as Noradrenaline (Norepinephrine) base	Noradrenaline 0.08 mg/ml solution for infusion	Noradrenaline 0.16 mg/ml solution for infusion	1mg / ml Concentrate for solution for infusion
Volume & presentation	50 ml Glass Vial	50 ml Glass Vial	50 ml Glass Vial	Glass Ampoules
Quantity of active substance per vial/ampoule	Each 50ml vial contains 500µg of noradrenaline tartrate corresponding to 250µg Noradrenaline base	Each 50 ml vial contains 8mg noradrenaline tartrate, corresponding to 4mg noradrenaline base	Each 50 ml vial contains 16 mg of noradrenaline tartrate corresponding to 8 mg of noradrenaline base.	Each ml of concentrate for solution for infusion contains 2 mg Noradrenaline tartrate, equivalent to 1 mg Noradrenaline base
indication	Restoration and maintenance of perioperative blood pressure following hypotension induced by spinal or general anaesthesia in adults.	Noradrenaline (Norepinephrine) is indicated in adults weighing over 50kg for the treatment of hypotensive emergencies.	Sinora solution for infusion is indicated in adults weighing over 50kg for the on-going treatment of hypotensive emergencies with escalating noradrenaline dose requirements.	Noradrenaline is indicated for the emergency restoration of blood pressure in cases of acute hypotension.
Dilution to provide	Ready to use	Ready to use (should NOT be diluted before use)	Ready to use (should NOT be diluted before use)	Dilution is required before use

Please click [here](#) to read the Summary of Product Characteristics for full details.



Call for Reporting

Please report suspected adverse drug reactions, including medication errors and inadequate therapeutic effects, to the MHRA through the Yellow Card scheme.

Please report:

- All suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason.
- All suspected ADRs associated with new drugs and vaccines identified by the black triangle ▼

You can report via:

- the Yellow Card website <https://yellowcard.mhra.gov.uk>
- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) for healthcare professionals

Alternatively, you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm.


When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset timing, treatment dates, and product brand name.

Adverse events should also be reported to Aguettant Ltd on 01275 463691.

Company contact details

If you have any questions or require further information, please contact the distributor of this product, namely Aguettant Ltd by phone on +353 (0)1 431 1350 or via email at info@aguettant.co.uk.

Kind regards

DocuSigned by:

Guillaume Sabatier
C5BCBBD7945D40F...

Guillaume SABATIER
Chief Operations Officer
Head Pharmacist